Structure based design of iminohydantoin BACE1 inhibitors: Identification of an orally available, centrally active BACE1 inhibitor

Jared N. Cumming(Merck & Co., Inc., Rahway, NJ, USA (United States)), Andrew W. Stamford(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yusheng Wu, Leonard Favreau(Merck & Co., Inc., Rahway, NJ, USA (United States)), Michael Czarniecki(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jianping Pan(Merck & Co., Inc., Rahway, NJ, USA (United States)), Eric M. Parker(University of New Hampshire), Matthew Kennedy(Merck & Co., Inc., Rahway, NJ, USA (United States)), William J. Greenlee, Reshma Kuvelkar(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kathleen Cox(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jeffrey Misiaszek, Johannes Voigt, Xia Chen(Merck & Co., Inc., Rahway, NJ, USA (United States)), Zhaoning Zhu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Elizabeth M. Smith(Merck & Co., Inc., Rahway, NJ, USA (United States)), Corey Strickland(Merck & Co., Inc., Rahway, NJ, USA (United States)), James Durkin(Merck & Co., Inc., Rahway, NJ, USA (United States)), Lynn A. Hyde(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ulrich Iserloh, Lingyan Wang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Brian A. McKittrick(Merck & Co., Inc., Rahway, NJ, USA (United States))
Bioorganic & Medicinal Chemistry Letters
February 16, 2012
Cited by 153


Related Papers